Recently, clinical investigations have shown that the IL-23/IL-17 signaling pathway contributes to the inflammatory reaction of Crohn's disease, psoriasis and systemic lupus erythematosus [18,23,24]. This evidence concerns the gene IL23A and systemic lupus erythematosus.